ATE347695T1 - Zellwanderungsassay - Google Patents

Zellwanderungsassay

Info

Publication number
ATE347695T1
ATE347695T1 AT02739361T AT02739361T ATE347695T1 AT E347695 T1 ATE347695 T1 AT E347695T1 AT 02739361 T AT02739361 T AT 02739361T AT 02739361 T AT02739361 T AT 02739361T AT E347695 T1 ATE347695 T1 AT E347695T1
Authority
AT
Austria
Prior art keywords
cell migration
migration assay
discrimination
kit
directed
Prior art date
Application number
AT02739361T
Other languages
English (en)
Inventor
Zheng Wei
Zhenhua Miao
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Application granted granted Critical
Publication of ATE347695T1 publication Critical patent/ATE347695T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5029—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell motility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Spectrometry And Color Measurement (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT02739361T 2001-06-07 2002-05-22 Zellwanderungsassay ATE347695T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29668201P 2001-06-07 2001-06-07
US10/154,399 US7282338B2 (en) 2001-06-07 2002-05-22 Cell migration assay

Publications (1)

Publication Number Publication Date
ATE347695T1 true ATE347695T1 (de) 2006-12-15

Family

ID=26851415

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02739361T ATE347695T1 (de) 2001-06-07 2002-05-22 Zellwanderungsassay

Country Status (10)

Country Link
US (3) US7282338B2 (de)
EP (2) EP1417488B1 (de)
JP (2) JP4233092B2 (de)
KR (2) KR100635703B1 (de)
AT (1) ATE347695T1 (de)
CA (1) CA2449628C (de)
DE (1) DE60216606T2 (de)
DK (1) DK1417488T3 (de)
ES (1) ES2274041T3 (de)
WO (1) WO2002101350A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE347695T1 (de) * 2001-06-07 2006-12-15 Chemocentryx Inc Zellwanderungsassay
WO2004024075A2 (en) * 2002-09-11 2004-03-25 Medical College Of Georgia Research Institute, Inc. Chemokine receptor antagonists as therapeutic agents
US7919083B2 (en) * 2002-11-15 2011-04-05 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
KR20060114381A (ko) * 2004-02-13 2006-11-06 레프로셀 인코퍼레이티드 배아줄기세포용 피더세포 작성 배지 및 피더세포
AU2006204750C1 (en) 2005-01-14 2012-11-01 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
PL2046762T3 (pl) 2006-07-14 2011-07-29 Chemocentryx Inc Triazolilofenylobenzenosulfonamidy
JP5380287B2 (ja) * 2006-07-18 2014-01-08 ノクソン・ファルマ・アクチエンゲゼルシャフト Sdf−1結合核酸
CA2692761C (en) 2007-07-12 2013-04-30 Chemocentryx, Inc. Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation
PT2190991T (pt) * 2007-08-06 2019-12-16 Noxxon Pharma Ag Ácidos nucleicos que se ligam a sdf 1 e a sua utilização
SG188220A1 (en) 2010-09-09 2013-04-30 Noxxon Pharma Ag Sdf-1 binding nucleic acids and the use thereof in cancer treatment
MX361929B (es) 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
CN104849377A (zh) * 2015-01-29 2015-08-19 衢州市质量技术监督检测中心 一种气质法快速测定畜禽肉中β-兴奋剂的前处理方法
IL294410B2 (en) 2016-11-23 2024-02-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
MX386699B (es) 2017-10-11 2025-03-19 Chemocentryx Inc Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2
US11995833B2 (en) 2020-07-31 2024-05-28 The Joan and Irwin Jacobs Technion-Cornell Institute System and method for on-phase microscopy
EP4740013A1 (de) * 2023-07-07 2026-05-13 AdAlta Limited Verbindung der rezeptorbelegung mit der wirksamkeit von cxcr4-antagonisten
KR102990665B1 (ko) * 2024-09-19 2026-07-15 부산대학교 산학협력단 Ccl5를 포함하는 골수 유래 줄기세포의 활성화 촉진용 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5284753A (en) 1991-03-20 1994-02-08 Neuro Probe, Inc. Multiple-site chemotactic test apparatus and method
SE9600820D0 (sv) * 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
US5928881A (en) * 1996-07-11 1999-07-27 Smithkline Beecham Corporation Method of identifying agonists and antagonist for CC-CKR5 receptor
GB9617923D0 (en) * 1996-08-28 1996-10-09 Smithkline Beecham Plc Novel receptor
US6153441A (en) * 1998-02-17 2000-11-28 Smithkline Beecham Corporation Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6649158B1 (en) * 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
AU2030000A (en) 1998-11-25 2000-06-13 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
US6329159B1 (en) 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
WO2000059941A1 (en) * 1999-04-08 2000-10-12 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
ATE347695T1 (de) * 2001-06-07 2006-12-15 Chemocentryx Inc Zellwanderungsassay

Also Published As

Publication number Publication date
US20050186556A1 (en) 2005-08-25
US7396653B2 (en) 2008-07-08
CA2449628C (en) 2008-05-06
JP2005518184A (ja) 2005-06-23
EP1717583A2 (de) 2006-11-02
EP1417488A4 (de) 2004-07-14
JP2009000113A (ja) 2009-01-08
DE60216606D1 (de) 2007-01-18
CA2449628A1 (en) 2002-12-19
KR100635703B1 (ko) 2006-10-17
WO2002101350A3 (en) 2004-03-11
DE60216606T2 (de) 2007-04-05
HK1065844A1 (en) 2005-03-04
EP1417488B1 (de) 2006-12-06
WO2002101350A2 (en) 2002-12-19
US20030017485A1 (en) 2003-01-23
KR100598309B1 (ko) 2006-07-10
JP4233092B2 (ja) 2009-03-04
EP1417488A2 (de) 2004-05-12
KR20040012888A (ko) 2004-02-11
KR20060054488A (ko) 2006-05-22
JP4340713B2 (ja) 2009-10-07
US7282338B2 (en) 2007-10-16
ES2274041T3 (es) 2007-05-16
DK1417488T3 (da) 2007-03-05
EP1717583A3 (de) 2007-10-10
US20070196855A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
DE60216606D1 (de) Zellwanderungsassay
DE60128002D1 (de) Rezeptor-nukleinsäure und rezeptor-polypeptide
ATE377654T1 (de) Ubiquitin-ligase-assay
DE60136562D1 (de) Heteroaryl-harnstoff-neuropeptid-y-y5-rezeptor-antagonisten
ATE267170T1 (de) Substituierte oxindolderivate als protein tyrosin kinase und als protein serin/threonin kinase inhibitoren
DE60131662D1 (de) Assayvorrichtung
DE60010420D1 (de) Automatisches Regressionstesten von Arbeitsplatzsoftware
ATE259060T1 (de) Codierung und decodierung von sensor-arrays mittels nanokristalle
ATE232200T1 (de) Neuropeptid y5-rezeptorantagonisten
NO20031284D0 (no) Direkte immunosensor-assay
DE60106607D1 (de) Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
NO20001100D0 (no) IL-8 reseptorantagonister
DE60141739D1 (de) Automatische Erkennung des Hintergrunds abgetasteter Vorlagen
EP1487865A4 (de) Verwendung von mit zytokinen verwandten reagentien von säugetieren
DK1036072T3 (da) Thrombinreceptorantagonister
ATE344241T1 (de) Benzyliden-1,3-dihydro-indol-2-on-derivate als inhibitoren von rezeptor tyrosine kinasesn, insbesondere von raf kinasen
ATE240954T1 (de) Oxazolidinone als 5-ht2a-antagonisten
ATE384257T1 (de) Energiemessung von photonen von biologischen assays
ATE381330T1 (de) Il-8 rezeptor-antagonisten
EP1023068A4 (de) ALPHA 1a ADRENOREZEPTOR-ANTAGONISTEN
DE69831413T2 (de) Il-8 rezeptor antagonisten
DE69824837D1 (de) Il-8-rezeptor-antagonisten
EP1014973A4 (de) ALPHA-1a-ADRENORECEPTOR ANTAGONISTEN
EP1533616A4 (de) Detektionskitt, darin zu verwendende assay-platte, detektionsverfahren, auswertungsverfahren, polyklonalantikörper von frosch-vitellogenin und prozess zur herstellung davon
TR200103642T2 (tr) Dişleri temizlemeye mahsus araç

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1417488

Country of ref document: EP